Guangdong Engineering & Technology Research Center for Quality and Efficacy Reevaluation of Post-market Traditional Chinese Medicine, Guangdong Key Laboratory of Plant Resources, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, P. R. China.
Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Drug Synthesis and Evaluation Center, Guangdong Institute of Applied Biological Resources, Guangzhou, P. R. China.
Pharm Biol. 2020 Dec;58(1):1006-1022. doi: 10.1080/13880209.2020.1821066.
Naoxintong Capsule (NXT), a Chinese medicine, has been widely used for the treatment of coronary heart disease (CHD) in clinics.
This study evaluated the cardioprotective effects of NXT alone and in combination with ticagrelor (TIC) and atorvastatin (ATO).
Qi deficiency and blood stasis rats were established by 8 weeks high fat diet feeding and 16 days exhaustive swimming and randomly divided into seven groups, that is, NXT (250, 500 and 1000 mg/kg/d), TIC (20 mg/kg/d), ATO (8 mg/kg/d), NXT (500 mg/kg/d)+TIC (20 mg/kg/d) and NXT (500 mg/kg/d)+ATO (8 mg/kg/d) group, with oral administration for 12 weeks. The contents of TC, TG, LDL-C, HDL-C, IL-1β, IL-6, IL-8, TNF-α, AST, ALT, SOD, MDA, CK-MB, LDH, TXA2, PGI2, IgA, IgG, IgM and C3 in serum were measured.
NXT + TIC group was significantly superior to the TIC group in decreasing the levels of TC (4.34 vs. 5.54), TG (3.37 vs. 4.66), LDL-C (1.21 vs. 1.35), LDH (4919.71vs. 5367.19) and elevating SOD level (248.54 vs. 192.04). NXT + ATO group was significantly superior to the ATO group in decreasing the levels of AST (195.931 vs. 241.63), ALT (71.26 vs. 83.16), LDH (4690.05 vs. 5285.82), TXA2 (133.73 vs. 158.67), IgG (8.08 vs. 9.80), C3 (2.03 vs. 2.35) and elevating the levels of HDL-C (1.19 vs. 0.91), SOD (241.91vs. 209.49).
The present findings demonstrate that the combined use of NXT with TIC and ATO had better integrated regulating effects than TIC and ATO, respectively. The mechanism of action requires further research.
脑心通胶囊(NXT)是一种中药,已广泛用于临床治疗冠心病(CHD)。
本研究评价了 NXT 单独使用以及与替格瑞洛(TIC)和阿托伐他汀(ATO)联合使用的心脏保护作用。
通过 8 周高脂饮食喂养和 16 天力竭游泳,建立气虚血瘀大鼠模型,随机分为 7 组,即 NXT(250、500 和 1000mg/kg/d)、TIC(20mg/kg/d)、ATO(8mg/kg/d)、NXT(500mg/kg/d)+TIC(20mg/kg/d)和 NXT(500mg/kg/d)+ATO(8mg/kg/d)组,口服给药 12 周。测量血清中 TC、TG、LDL-C、HDL-C、IL-1β、IL-6、IL-8、TNF-α、AST、ALT、SOD、MDA、CK-MB、LDH、TXA2、PGI2、IgA、IgG、IgM 和 C3 的含量。
NXT+TIC 组在降低 TC(4.34 比 5.54)、TG(3.37 比 4.66)、LDL-C(1.21 比 1.35)、LDH(4919.71 比 5367.19)和升高 SOD 水平(248.54 比 192.04)方面明显优于 TIC 组。NXT+ATO 组在降低 AST(195.931 比 241.63)、ALT(71.26 比 83.16)、LDH(4690.05 比 5285.82)、TXA2(133.73 比 158.67)、IgG(8.08 比 9.80)、C3(2.03 比 2.35)和升高 HDL-C(1.19 比 0.91)、SOD(241.91 比 209.49)水平方面明显优于 ATO 组。
本研究结果表明,与 TIC 和 ATO 分别使用相比,NXT 与 TIC 和 ATO 联合使用具有更好的综合调节作用。其作用机制需要进一步研究。